Shanghai Tofflon Science Tech (300171) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Tofflon Science Tech (300171) has a cash flow conversion efficiency ratio of 0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥47.30 Million ≈ $6.92 Million USD) by net assets (CN¥8.09 Billion ≈ $1.18 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Tofflon Science Tech - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Shanghai Tofflon Science Tech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai Tofflon Science Tech total liabilities for a breakdown of total debt and financial obligations.
Shanghai Tofflon Science Tech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Tofflon Science Tech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Tapai Group Co Ltd
SHE:002233
|
0.040x |
|
Herbalife Nutrition Ltd
F:HOO
|
-0.229x |
|
Grainger PLC
F:1U4
|
0.015x |
|
Legend Holdings Corporation
F:1PC
|
-0.009x |
|
Shandong Yulong Gold Co Ltd
SHG:601028
|
-0.041x |
|
Blackrock Municipal Target Term Closed Fund
NYSE:BTT
|
0.027x |
|
YOUZU Interactive Co Ltd
SHE:002174
|
0.007x |
|
Jiangsu Wujiang Rural Coml Bk
SHG:603323
|
0.056x |
Annual Cash Flow Conversion Efficiency for Shanghai Tofflon Science Tech (2007–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Tofflon Science Tech from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 300171 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
CN¥880.61 Million ≈ $128.86 Million |
0.109x | +384.10% |
| 2023-12-31 | CN¥8.11 Billion ≈ $1.19 Billion |
CN¥-312.38 Million ≈ $-45.71 Million |
-0.039x | -219.14% |
| 2022-12-31 | CN¥7.64 Billion ≈ $1.12 Billion |
CN¥247.15 Million ≈ $36.17 Million |
0.032x | -89.42% |
| 2021-12-31 | CN¥4.48 Billion ≈ $655.32 Million |
CN¥1.37 Billion ≈ $200.32 Million |
0.306x | +1.20% |
| 2020-12-31 | CN¥3.69 Billion ≈ $540.54 Million |
CN¥1.12 Billion ≈ $163.28 Million |
0.302x | +119.46% |
| 2019-12-31 | CN¥3.24 Billion ≈ $474.49 Million |
CN¥446.31 Million ≈ $65.31 Million |
0.138x | +93.23% |
| 2018-12-31 | CN¥3.12 Billion ≈ $456.14 Million |
CN¥222.04 Million ≈ $32.49 Million |
0.071x | +950.96% |
| 2017-12-31 | CN¥3.09 Billion ≈ $451.60 Million |
CN¥20.92 Million ≈ $3.06 Million |
0.007x | -81.07% |
| 2016-12-31 | CN¥3.00 Billion ≈ $438.97 Million |
CN¥107.41 Million ≈ $15.72 Million |
0.036x | -24.96% |
| 2015-12-31 | CN¥2.95 Billion ≈ $431.38 Million |
CN¥140.66 Million ≈ $20.58 Million |
0.048x | +131.95% |
| 2014-12-31 | CN¥2.68 Billion ≈ $391.66 Million |
CN¥55.06 Million ≈ $8.06 Million |
0.021x | -85.39% |
| 2013-12-31 | CN¥2.41 Billion ≈ $352.36 Million |
CN¥338.95 Million ≈ $49.60 Million |
0.141x | -9.76% |
| 2012-12-31 | CN¥2.23 Billion ≈ $325.86 Million |
CN¥347.38 Million ≈ $50.83 Million |
0.156x | +185.77% |
| 2011-12-31 | CN¥2.08 Billion ≈ $304.19 Million |
CN¥113.47 Million ≈ $16.60 Million |
0.055x | -84.69% |
| 2010-12-31 | CN¥331.97 Million ≈ $48.58 Million |
CN¥118.39 Million ≈ $17.32 Million |
0.357x | -36.58% |
| 2009-12-31 | CN¥211.83 Million ≈ $31.00 Million |
CN¥119.11 Million ≈ $17.43 Million |
0.562x | +47.46% |
| 2008-12-31 | CN¥147.32 Million ≈ $21.56 Million |
CN¥56.17 Million ≈ $8.22 Million |
0.381x | +34.11% |
| 2007-12-31 | CN¥113.69 Million ≈ $16.64 Million |
CN¥32.32 Million ≈ $4.73 Million |
0.284x | -- |
About Shanghai Tofflon Science Tech
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laborato… Read more